SAN DIEGO--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX), a biopharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, and for which there are currently limited patient options, today announced the pricing of an underwritten public offering of 6,840,000 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Retrophin from this offering, before deducting underwriting discounts and commissions and offering expenses payable by Retrophin, are expected to be approximately $130.0 million. Retrophin has granted the underwriters a 30-day option to purchase up to an aggregate of 1,026,000 additional shares of common stock. The offering is expected to close on or about March 24, 2015, subject to customary closing conditions. Retrophin anticipates using the net proceeds from the offering to fund its research and development efforts, acquisitions or investments in additional complementary businesses, products and technologies, including $27 million to fund the initial cash milestone payment payable in connection with the acquisition of an additional clinical asset from Asklepion Pharmaceuticals, LLC, and for general corporate purposes, including working capital.
Help employers find you! Check out all the jobs and post your resume.
